Research
Metabolic adaptation
Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).
Clinicians should consider that patients with T2D may experience less weight loss from incretin therapies compared to those with obesity alone.
StrongSupportsmedium confidence
Placebo-adjusted weight loss was significantly lower in T2D versus obesity trials (pooled ratio: 0.61, 95% C.I. 0.56; 0.67).
Why this rating
Based on a meta-regression of multiple RCTs.
Source
Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression
Marella Marassi et al. · Nutrition Metabolism and Cardiovascular Diseases · 2026
Meta-analysis
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →